The PennZone

PHILADELPHIA, May 4, 2021 /PRNewswire/ -- ExtriCARE USA, a national medical device company specializing in negative pressure wound therapy (NPWT) distribution, is excited to introduce hybrid technology to the wound care market.

The company firmly believes NPWT is still in its infancy stage. There is a tremendous opportunity for growth and innovation because this niche market is evolving. ExtriCARE USA recognizes the potential and is proactively investing in the future of NPWT, which will lead to more positive results for medical equipment providers, clinicians and patients.

ExtriCARE USA has developed a new concept to take the NPWT evolution to the next stage. They plan to positively disrupt the market with hybrid technology that brings versatility to the next level. This concept, coined as hNPWT, will provide patients with a continuum of care necessary to heal wounds more efficiently.

More on The PennZone

• Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
• Veterans Day Breakfast Celebration in Valley Forge to Honor America's Military Heroes
• Best Black Friday 2026 Deals on Lightweight Foldable Electric Wheelchairs – Save Up to 60%
• Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
• Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations

Currently, there are two primary applications of NPWT—traditional (tNPWT) and single-use (sNPWT). ExtriCARE USA understands wound healing is not a uniform approach. Through hybrid technology (hNPWT), clinicians can tailor the application based on the patients' distinct needs.

ExtriCARE USA's hybrid model will allow clinicians to be more efficient by simplifying the NPWT process. This hybrid system allows for one pump to utilize both silicon incisional and traditional foam dressing kits. Clinicians will confidently apply which approach will be best suited for the patient.

"Hybrid technology is the future of NPWT," said Peter Mason, President. "Our new product line will be the most adaptable NPWT system in the wound care industry."

When developing new medical devices, it's essential to consider the wide variety of preferences and benefits to all approaches. ExtriCARE USA's hybrid model significantly considers this by giving clinicians the freedom to make their own decisions and work around the patient's needs.

More on The PennZone

• Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
• Dr. Marilyn Pendelton Releases The Grief Reset to Address Grief Beyond Death
• AeroNet Deploys netElastic vBNG and CGNAT with Tarana Wireless to Deliver Scalable, Fiber-Class Broadband Across Puerto Rico
• New Atlas Maps the 38 States Behind Every Conversation
• Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election

ExtriCARE USA is working closely with manufacturer Alleva Medical to design the new product line to bring this hybrid concept to life.

For press inquiries or more information, please contact Binh Nguyen at 717-389-2928 or [email protected].

About ExtriCARE USA:
ExtriCARE USA is a national medical device distribution company specializing in negative pressure wound therapy (NPWT). Our products save clinicians time and benefit patients by introducing solutions that are mobile and provide a more flexible therapy. To learn more, visit www.extricareusa.com.

SOURCE ExtriCARE USA

Related Links

https://extricareusa.com

---

Show All News | Disclaimer | Report Violation